Advertisement

Topics

PubMed Journals Articles About "Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic" RSS

09:57 EDT 23rd September 2018 | BioPortfolio

Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic articles that have been published worldwide.

More Information about "Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic" on BioPortfolio

We have published hundreds of Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic news stories on BioPortfolio along with dozens of Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic Clinical Trials and PubMed Articles about Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic Companies in our database. You can also find out about relevant Expanding Disease Definitions Unnecessarily Labelling Women With Polycystic Drugs and Medications on this site too.

Showing "expanding disease definitions unnecessarily labelling women with polycystic" PubMed Articles 1–25 of 27,000+

Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.

Polycystic ovary syndrome is one of the most common endocrinopathies in young women, and it affects 6% to 8% of women in reproductive age. Hyperandrogenism is the hallmark of polycystic ovary syndrome. The aim of the present study was to evaluate the effects of orlistat on weight loss and serum androgen levels among Iranian women with polycystic ovary syndrome.


Clinical, Hormonal, and Metabolic Parameters in Women with Subclinical Hypothyroidism and Polycystic Ovary Syndrome: A Cross-Sectional Study.

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive age women, yet its clinical presentation shares similarities with several other endocrine disorders such as thyroid disease. Hence, the objective of this study was to further evaluate this association by investigating the clinical, hormonal, and metabolic parameters between subclinical hypothyroidism (SCH) and PCOS.

Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.

Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an increased risk of nonalcoholic fatty liver disease (NAFLD) in individuals with PCOS and implicated androgen excess as a potential driver.


Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?

For some time, it has been assumed that women with polycystic ovary syndrome (PCOS) are at increased risk of developing cardiovascular disease (CVD). This has largely been on the basis of having many risk factors, including abnormal lipid profile, insulin resistance, and markers of inflammation. However, despite having these and other risk factors, we argue here, in the view of the authors, that there is no credible evidence that there is greater CVD morbidity in all women with PCOS. We analyze the existing...

The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome.

To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS).

Sharp liver excision under hepatic vascular exclusion in case of liver transplant for large polycystic disease. Case report of a new surgical technique.

Polycystic liver disease is observed in 75-90% of patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD has a high prevalence of 1/1000. Hepatomegaly severely reduces quality of life and liver transplantation seems to be method of choice for many patients. Because of the rarity of this disease and the small number of symptomatic patients with massive hepatomegaly indicated for the transplantation, there is no standard approach for explantation of the liver.

Development of a question prompt list for women with polycystic ovary syndrome.

To develop a question prompt list (QPL) for women with polycystic ovary syndrome (PCOS) and explore its acceptability and feasibility.

Why we need epidemiologic studies of polycystic ovary syndrome in Africa.

Polycystic ovarian syndrome (PCOS) is a common endocrine-metabolic disorder. Although it is most clinically apparent among women of reproductive age, PCOS can be symptomatic in pre-adolescent and menopausal women, and potentially even in men [1]. Typically, the syndrome is characterized by chronic oligo-anovulation, biochemical and/or clinical hyperandrogenism, and polycystic ovarian morphology (PCOM). In addition to hyperandrogenic dermatologic symptoms (acne, alopecia, and hirsutism), PCOS is associated w...

Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.

Oxidative stress is evident from an early stage in chronic kidney disease (CKD). Therefore, we investigated redox biomarkers in polycystic kidney disease (ADPKD) and IgA nephropathy (IGAN).

Impact of liver volume on polycystic liver disease-related symptoms and quality of life.

Symptoms in polycystic liver disease (PLD) are thought to be caused by compression of organs and structures by the enlarged liver.

A New Approach to Defining Disease.

In this paper, we examine recent critiques of the debate about defining disease, which claim that its use of conceptual analysis embeds the problematic assumption that the concept is classically structured. These critiques suggest, instead, developing plural stipulative definitions. Although we substantially agree with these critiques, we resist their implication that no general definition of "disease" is possible. We offer an alternative, inductive argument that disease cannot be classically defined and th...

Characterization of long non-coding RNA and messenger RNA profiles in follicular fluid from mature and immature ovarian follicles of healthy women and women with polycystic ovary syndrome.

Do long non-coding RNA (lncRNA) and messenger RNA (mRNA) profiles in follicular fluid from mature and immature ovarian follicles differ between healthy women and women with polycystic ovary syndrome (PCOS)?

Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome.

To investigate the effects of a supervised aerobic exercise training intervention on health-related quality of life (HRQL), cardiorespiratory fitness, cardiometabolic profile, and affective response in overweight/obese women with polycystic ovary syndrome (PCOS).

Prevalence of vitamin D deficiency in infertile women with polycystic ovarian syndrome and its association with metabolic syndrome - A prospective observational study.

The main purpose of this study was to determine the prevalence of vitamin D deficiency in infertile women with polycystic ovarian syndrome (PCOS) and to explore the association of hypovitaminosis D with metabolic syndrome in women with PCOS.

The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome.

The aim of this study was to evaluate the effect of the co-administration of vitamin D and omega-3 fatty acid on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome (PCOS).

Inositol for women with polycystic ovary syndrome - possibly just better than placebo.

We read the review by Tanbo et al. with great interest (1). The authors propose their management approach for unovulatory women diagnosed with polycystic ovary syndrome (PCOS) for whom a variety of treatment options exist. Although the authors performed a comprehensive review of published data, we believe that their main conclusion regarding the preferred therapeutic approach requires further consideration. This article is protected by copyright. All rights reserved.

Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.

Polycystic ovary syndrome (PCOS) affects 5%-15% of women and is the most common cause of hirsutism. Data on the time-course of improvement to suppressive therapy and predictors of that response in PCOS are lacking. The objectives of our study are to determine the long-term response and identify predictors of response in PCOS women treated with suppressive therapy, including spironolactone (SPL) + oral contraceptives (OCs).

Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Comparison of Management Approaches.

Autosomal dominant polycystic kidney disease (ADPKD) is a risk factor for formation of intracranial aneurysms (IAs), though the ideal screening and treatment strategies in this population are unclear.

Cognitive-behavioral therapy improves weight loss and quality of life in women with polycystic ovary syndrome: a pilot randomized clinical trial.

To compare the effects of cognitive-behavioral therapy (CBT) and lifestyle modification (LS) versus LS alone on weight, depressive and anxiety symptoms, and stress response in women with polycystic ovary syndrome (PCOS), overweight/obesity, and depressive symptoms.

What Can You Find about Polycystic Ovary Syndrome (PCOS) Online? Assessing Online Information on PCOS: Quality, Content, and User-Friendliness.

 Polycystic ovary syndrome (PCOS) is a common yet complex condition, where education is vital. It predominantly affects reproductive-aged women, the age group with peak use of the Internet, now a major source of health information. Women with PCOS are dissatisfied with care, and the lack of useful online information is a key concern.

What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?

Recommendations regarding "treat to target" in psoriatic arthritis (PsA) have stated that the target should be remission or inactive disease. Potential definitions include very low disease activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Activity Index for PsA (DAPSA) or clinical DAPSA (cDAPSA) remission. Our aim was to investigate the proportion of patients who fulfill these definitions and how much residual active disease remained.

Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome.

To formulate clinical consensus recommendations for screening depression, anxiety, health-related quality of life (HRQoL), and disordered eating symptoms in women with polycystic ovary syndrome (PCOS) and review prevalence based on phenotypes and ethnicity, changes over time, etiology, and impact of treatment.

Testosterone levels in 3rd trimester in polycystic ovary syndrome. Odense Child Cohort.

Polycystic ovary syndrome is characterized by hyperandrogenism. In pregnancy, testosterone levels may be higher in women with PCOS compared to controls.

Burden of Psoriatic Arthritis in different definitions of disease activity: comparing Minimal Disease Activity and Disease Activity index for Psoriatic Arthritis.

Treat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target Minimal Disease Activity (MDA) and the articular target Disease Activity index for PsA (DAPSA). We aimed to compare burden of PsA in patients with low disease activity according to the two definitions MDA and DAPSA-Low Disease Activity (DAPSA-LDA), one year after diagnosis.

Quantitative magnetic resonance imaging (MRI) assessments of autosomal recessive polycystic kidney disease (ARPKD) progression and response to therapy in an animal model.

Autosomal Recessive Polycystic Kidney Disease (ARPKD) is associated with significant mortality and morbidity and there are currently no disease-specific treatments available for ARPKD patients. One major limitation in establishing new therapies for ARPKD is a lack of sensitive measures of kidney disease progression. Magnetic Resonance Imaging (MRI) can provide multiple quantitative assessments of disease.


Advertisement
Quick Search
Advertisement
Advertisement